Clinical evaluation of an improved injectable microcapsule contraceptive system
| Autor: | Thomas R. Tice, Walter H. Wilborn, Charles E. Flowers, V. Z. Pope, Lee R. Beck |
|---|---|
| Rok vydání: | 1983 |
| Předmět: |
Adult
Ovulation medicine.medical_specialty Time Factors Norethisterone Polymers media_common.quotation_subject Population Capsules Injections Intramuscular Endometrium Follicle-stimulating hormone Pharmacokinetics Internal medicine Contraceptive Agents Female medicine Humans education Polyglactin 910 Menstrual cycle media_common education.field_of_study business.industry Obstetrics and Gynecology Biodegradation Environmental Endocrinology Evaluation Studies as Topic Delayed-Action Preparations Female Norethindrone business Luteinizing hormone Intramuscular injection medicine.drug |
| Zdroj: | American Journal of Obstetrics and Gynecology. 147:815-821 |
| ISSN: | 0002-9378 |
| DOI: | 10.1016/0002-9378(83)90046-7 |
| Popis: | Pharmacokinetics and pharmacodynamics of a long-acting injectable microcapsule, poly(DL-lactide-co-glycolide), delivery system were tested in 10 women. Two doses (75 or 100 mg of norethindrone) were administered by intramuscular injection. Treatment suppressed ovarian function and inhibited ovulation for 3 months in all subjects. Levels of norethindrone in subjects who received the 100 mg dose were proportionately higher than those in subjects who received the 75 mg dose. Subsequent to the injection, there was a rapid rise in the serum levels of norethindrone followed by a gradual decline until 8 to 10 weeks. Between 10 and 20 weeks after treatment, there was a secondary rise and fall in the serum levels of norethindrone. Treatment caused suppression of the endometrium for 3 months, and, except for spotting and irregular menstrual cycles, there were no adverse side effects. Treatment had no significant effect on serum lipids. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|